Jane Street
RAPP

Jane Street’s Rapport Therapeutics RAPP Stock Holding History

Jane Street’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-51,100
Closed -$1.52M – 12664
2025
Q3 		$1.52M Buy
+51,100
New +$912K ﹤0.01% 5449

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Jane Street's RAPP Position: Q4 2025 in Review

Jane Street sold out of Rapport Therapeutics (RAPP) in Q4 2025, closing a stake of 46,223 shares — an estimated $1.28M sold.

Jane Street first reported a position in RAPP in Q3 2025 and held it in 1 quarter. The position peaked at $1.37M in Q3 2025. 144 funds tracked by Wall St. Rank hold RAPP as of Q4 2025.

  • Jane Street reported no remaining Rapport Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 46,223 Rapport Therapeutics shares in Q4 2025, an estimated $1.28M.
  • Jane Street first reported a position in Rapport Therapeutics in Q3 2025 and held it in 1 quarter.
  • Jane Street's Rapport Therapeutics position peaked at $1.37M in Q3 2025.
  • 144 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.